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Abstract
A cornerstone of HIV prevention clinical trials is providing a combination prevention package to all trial participants.
The elements included in that standard of care (SoC) package evolve as new prevention modalities are developed.
Pre-exposure prophylaxis (PrEP) was recommended by the World Health Organization for persons at high risk of
acquiring HIV, but not all countries immediately adopted those recommendations. The South African Medical
Research Council (SAMRC) convened a summit to discuss issues relating to SoC and PrEP in HIV prevention clinical
trials taking place in lower- to middle-income countries (LMIC). Policymakers, regulators, ethicists, experts in law,
researchers, representatives of advocacy groups, and the HIV Vaccine Trials Network (HVTN) presented a framework
within which SoC principles could be articulated. A group of subject matter experts presented on the regulatory,
ethical, scientific, and historic framework of SoC in clinical trials, focusing on PrEP in South Africa. Summit
participants discussed how and when to include new HIV treatment and prevention practices into existing clinical
guidelines and trial protocols, as well as the opportunities for and challenges to scaling up interventions. The
summit addressed challenges to PrEP provision, such as inconsistent efficacy amongst different populations and
various biological, virological, and immunological explanations for this heterogeneity. Advocates and community
members propagated the urgent need for accessible interventions that could avert HIV infection. The meeting
recommended supporting access to PrEP in HIV prevention trials by (1) developing PrEP access plans for HIV
vaccine trials, (2) creating a PrEP fund that would supply PrEP to sites conducting HIV prevention trials via a central
procurement mechanism, and (3) supporting the safety monitoring of PrEP. This report summarizes the
presentations and discussions from the summit in order to highlight the importance of SoC in HIV prevention
clinical trials.
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Introduction
HIV prevention has evolved tremendously over the last
decade. Traditionally, antiretroviral therapy (ART) was
prescribed to people living with HIV (PLWH) to slow the
progression of AIDS when CD4+ T-cell counts dipped
below 200 cells per microliter. As ART reduces viral load,
it was hypothesized to work as ‘treatment as prevention’
(TasP) to inhibit sexual transmission. In a trial of serodis-
cordant couples that compared early ART administration
(irrespective of CD4 counts) to delayed, the early treat-
ment reduced the risk of sexual HIV transmission to their
uninfected partner by over 90% [1, 2]. This study, con-
ducted by the HIV Prevention Trials Network (HPTN)
HPTN 052, has since been joined by other trials that have
shown undetectable viral loads prevent transmission and
solidified the use of ART for TasP [3, 4].
The ‘inverse’ of HPTN 052 was investigating the effi-
cacy of ART when administered to the HIV-uninfected
partner in a serodiscordant relationship, a concept of
pre-exposure prophylaxis (PrEP). Several randomized
controlled trials (RCTs) comparing different combina-
tions of oral tenofovir disoproxil fumarate (TDF) and
TDF/emtricitabine (TDF/FTC, brand name Truvada) in
serodiscordant couples have shown that PrEP can reduce
HIV acquisition, although to different extents based on
the population [5–7]. Prevention efficacy is robust in
men, but contradictory results have been reported in
women [5–9].
A cornerstone of HIV prevention clinical trials is pro-
viding a combination prevention package (e.g. risk re-
duction counselling, free condoms, diagnosis, and
treatment for STIs) to all trial participants. The package
provision is part of an obligation to minimize the partici-
pants’ risk of acquiring HIV, as assumption of risk can
be underestimated in RCT participants [10, 11]. As new
prevention modalities emerge, the prevention packages
are adapted accordingly to provide the best care to par-
ticipants whilst considering cost, population impact/effi-
cacy, government and other funders’ roles, and clinical
science integrity. In 2010, after iPrEx results showed
PrEP efficacy in men who have sex with men (MSM)
and transgender women, the HIV Vaccine Trials Net-
work (HVTN) held a series of consultations with advo-
cates, ethicists, and other stakeholders; surveys of
participants; and discussions with protocol team leader-
ship and research site investigators to evaluate the pros
and cons of potential approaches to PrEP access in an
ongoing HIV vaccine efficacy trial (HVTN 505) [12].
The group considered three options (ranging from pro-
viding information on PrEP to providing PrEP itself) and
four main issues: researcher obligation to participants
and their communities, effects on study design, health
policy recommendations, and stakeholder opinions. The
consensus was to provide PrEP information and referrals
for PrEP access. For the latter, Gilead donated Truvada
for any interested participant and the HVTN coordi-
nated a contract with a mail-order pharmacy to ease ac-
cess. As HVTN 505 was conducted only in the United
States (US), ethical issues about differential health re-
sources and regulatory standards in other countries were
not addressed. Following this prevention package
amendment, in 2012, PrEP was approved for use in pop-
ulations at high risk of HIV infection in the US by the
Food and Drug Administration [13].
In 2015, the World Health Organization (WHO) made
a recommendation for the inclusion of oral PrEP as part
of a combination HIV prevention package for people at
substantial risk of HIV infection [14]. In 2017, TDF/FTC
was licensed for use as PrEP in 17 countries and was in-
cluded in the WHO Essential Medicines List (EML). At
that time, although PrEP was approved in South Africa,
its availability was limited to the National Department of
Health (NDoH)-sanctioned sub-populations (specifically
MSM and sex workers) and research-led demonstration
projects. Unfortunately, this precluded heterosexual girls
and women access to PrEP. Due to the high prevalence
of HIV in women in South Africa, up to 24% in some
areas [15], this population makes up a large proportion
of participants in HIV prevention clinical trials con-
ducted there. A substantial gap existed between partici-
pants in HIV prevention trials and local access to
comprehensive prevention packages. The South African
Medical Research Council (SAMRC) has a mandate to
address issues that could potentially impact the conduct
of health research, including clinical trials. As such, the
SAMRC together with the HVTN convened a summit in
Cape Town in 2017 to address PrEP access as a case
study on the standard of care (SoC) in clinical trials in
lower- and middle-income countries (LMIC). Whilst the
summit focused on PrEP provision in South Africa, the
issues raised are applicable to other forms of SoC across
LMICs. This article summarizes the viewpoints and dis-
cussions that took place in November 2017 at the
summit.
Methods
As a result of the lack of PrEP licensure for those at high
risk of HIV acquisition in South Africa, the SAMRC
reached out to stakeholders in communities, govern-
ment, academia, and pharmaceutical companies to dis-
cuss issues concerning PrEP provision as SoC in HIV
prevention trials. The 2-day summit began with presen-
tations from experts on ethics, regulatory processes, clin-
ical studies, basic science, and community engagement,
followed by a day of panel discussions with the goal of
providing a comprehensive and thought-out plan on
PrEP provision for HIV prevention trials in-country. The
overall objective of the meeting was to engage
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regulatory, legal, and ethical frameworks, whilst consid-
ering perspectives of government, community organiza-
tions and advocates, and the funders of research to
review the principles behind setting SoC for prevention
clinical trials in LMIC to address the PrEP gap. There
were 18 presentations on the first day (Supplemental
Table 1) and three panel discussions on day 2. Both days
were recorded and transcribed. This report summarizes
the main themes from the summit, which resulted in a
recommendation and Executive Statement from the
SAMRC [16]. An Epilogue provides an update of what
has happened in this space since the summit took place
in 2017.
Objectives:
 To outline what a SoC is and whether PrEP falls
into this category for HIV prevention clinical trials
in South Africa
 To present context of PrEP efficacy in South African
females
 To discuss the approaches of how to provide PrEP
as a SoC in HIV prevention trials in South Africa
Themes of the summit
Use of local and international guidelines to define SoC in
efficacy trials
A modern definition of SoC is ‘that which a minimally
competent physician in the same field would do under
similar circumstances’ [17]. In the context of HIV vac-
cine RCT, SoC includes a basic prevention package that
every participant has access to regardless of whether
they receive vaccine or placebo. Local regulatory bodies
ensure clinical trials include SoC and adhere to guide-
lines such as Sections 21 and 19 of the Medicines and
Related Substances Act and General Regulations [18],
the Nuremberg Code, Declaration of Helsinki and the
Belmont Report [19–21], and the International Council
for Harmonisation of Technical Requirements for Phar-
maceuticals for Human Use (ICH) on Good Clinical
Practice (GCP) [22, 23]. GCP requires clinical trial SoC
to include informed consent, information about adverse
outcomes, potential for post-trial treatment, and adverse
drug event reporting. The South African Bill of Rights
discusses the right to health in Section 27 of the Consti-
tution: ‘The state has to take reasonable legislative mea-
sures within its available resources.’ The WHO, US
Centers for Disease Control and Prevention (CDC),
South African NDoH, and South African HIV Clinicians
Society all have HIV prevention/treatment trial guide-
lines available. The purpose of these international guide-
lines on SoC is to promote consistency and ensure
equity in clinical trials globally.
However, the definition of SoC can vary depending on
context or location. PrEP licensure for ‘those at risk of
HIV’ is such an example. Apart from a universal SoC, an
international consensus standard considers SoC factors
such as cost, the balance between desirable and undesir-
able effects, and acceptability to those who will receive
treatment [24–26]. The SAMRC has funded the South Af-
rican Guidelines Excellence (SAGE) project, which is a
multi-partner, 5-goal project to develop and implement
primary care guidelines in South Africa [27]. SAGE applies
stakeholder expertise to efficiently identify and address re-
source limitations in SoC across the diverse health care
system of South Africa. The SAGE project is in the midst
of evaluating PrEP use for women in South Africa.
In 1996, the NDoH implemented the South African
Standard Treatment Guidelines and Essential Medicines
List (STG/EML), which determines access to and avail-
ability of medicines in the public sector, to ensure SoC
for its citizens. Four criteria must be met for a medica-
tion to be approved to the EML: (1) public health need;
(2) safety, efficacy, and quality; (3) pharma-economics/
cost; and (4) practice considerations. In 2017, PrEP was
not part of the EML although 26 countries had adopted
the WHO recommendations for its use [28].
Historical precedent for implementing new SoC for HIV
prevention in South Africa
South Africa has, in the past, adopted international SoC
guidelines for the prevention of mother-to-child transmis-
sion (PMTCT) of HIV. In 2002, the non-governmental
organization Treatment Action Campaign (TAC) filed a
lawsuit against the South African government over its lim-
ited ‘duty of care’ distribution of the antiretroviral drug
nevirapine [29]. The government at the time denied scien-
tific evidence surrounding HIV/AIDS and the Ministry of
Health was opposed to any form of nevirapine rollout.
TAC argued these limitations put PLWH and their new-
borns at a substantial health risk, violating their constitu-
tional rights. The court ruled in favour of TAC that the
government’s limited supply was unconstitutional as it de-
nied nevirapine administration in the public health system
where there was capacity and its use was medically indi-
cated [30, 31].
In 2013, the Joint United Nations Programme on HIV/
AIDS (UNAIDS) developed a new SoC for PMTCT of
HIV. The new SoC, called Option B+, was to replace the
previously used Options A and B that involved different
ART regimens [32]. There was a large local debate after
the international community proposed that South Africa
implement Option B+, as the country was doing reason-
ably well with Options A/B. As it turned out, it was the
right decision to move to Option B+; South Africa low-
ered the MTCT rate from 8% in 2009 to 2% in 2015
[33]. South African researchers used local data to make
Miner et al. Trials          (2021) 22:778 Page 3 of 8
decisions based on the international guidance. This ex-
emplifies how global decision-making can affect local
SoC guidelines in South Africa.
Implications of conflicting PrEP efficacy data for South
African women
As stated before, SoC can vary based on context or re-
gion. The economic strength/status and medical infra-
structure of a nation, city, or village can profoundly
impact the type of health care its citizens receive. South
Africa is one of the most unequal societies in the world,
with a Gini coefficient of 0.63 [34] and an annual health
expenditure of 8.2% gross national product [35]. There
were an estimated 7.7 million PLWH in 2017, equating
to an overall prevalence of ~ 14% [15]. However, hetero-
sexual females are one of the most at-risk groups with
an estimated prevalence of 24%. This is in contrast to,
for example, the US where MSM and transgender
women are at the highest risk (~ 12% prevalence) [36,
37].
In fact, the discrepancy in PrEP efficacy between MSM
and heterosexual women is a major factor in its omis-
sion from the South African EML. A systematic review
of oral PrEP RCT across a range of populations and set-
tings concluded that it was effective in reducing HIV in-
fection risk across gender, PrEP regimen, dosing, and
mode of acquisition [38], and numerous studies have
shown high efficacy of oral PrEP in MSM populations
[6, 39–41]. Table 1 outlines the five efficacy trials of oral
PrEP that enrolled women to date: Partners PrEP,
Bangkok TDF, FEM-PrEP, VOICE, and TDF2. As
depicted in the table, efficacy in heterosexual women is
inconsistent. Numerous confounders have been sug-
gested for the discrepancy, including biological factors
(e.g. viral subtype, vaginal microenvironment) and be-
havioural factors (e.g. drug adherence, relationship sta-
tus). In fact, a meta-analysis of these trials found that
adherence to PrEP correlated with efficacy [43], and un-
fortunately, adherence has been lower for women in
LMIC than MSM in high-income countries. Further data
will be required to refine the estimates of PrEP efficacy
in southern African women to aid in appropriate messa-
ging, characterizing the impact of PrEP at a population
level and within HIV prevention efficacy trials and un-
derstanding conditions that might compromise efficacy
[43]. Despite these unknowns, the South African AIDS
Committee guidelines included the provision of daily
PrEP for high-risk populations in 2016 [44].
Ethics committees responsible for evaluating SoC in
clinical trials face a dilemma when there is a lack of con-
sensus in the scientific community. In 2005, a prominent
South African ethicist encouraged researchers that,
‘Contributing to sustainable improvements in health by
progressively ratcheting the SoC upwards for research
participants and their communities is an ethical obliga-
tion of those resource-rich countries who sponsor and
implement research in poorer ones’ [45]. In 2016, the
US-based ethicist Jeremy Sugarman referred to what is
now highly quoted as the ‘rebuttable presumption’ [46].
According to Sugarman, the onus was placed on re-
searchers to justify not offering PrEP to participants in
HIV prevention trials. But, as stated before, this is not a
simple issue when local governments do not provide that
SoC to everyone in the target community.
The National PrEP Technical Working Group and PrEP
availability in South Africa
In October 2015, the NDoH convened a meeting to con-
sider the soon-to-be-released WHO guidelines recom-
mending PrEP use for all populations at substantial risk
of HIV. At that meeting, the National PrEP Technical
Working Group was formed, which has been an import-
ant vehicle for guiding PrEP introduction into South Af-
rica. Shortly thereafter, the Medicines Control Council
licensed TDF/FTC for PrEP use and, by June 2016, the
beginnings of a publicly funded programme began where
PrEP was provided to sex workers as part of the Na-
tional Sex Worker Program. It was one of the first na-
tionally funded PrEP programmes in Africa and was
lauded by UNAIDS [47]. Between 2016 and 2017, pub-
licly funded programmes provided nearly 3000 PrEP ini-
tiations at 17 sites across South Africa. A key take-home
from the National Sex Worker Program data was that
initially uptake was quite low, partly because prior to li-
censure, sex workers were sceptical as to the motives of
including them in a programme. But with increasing
awareness of PrEP and perhaps expansion of access to
other populations, hesitancy seemed to decrease.
Since the kick-off of the National Sex Worker Pro-
gram, the National PrEP Technical Working Group
began implementing demonstration projects for adoles-
cent girls and young women. Those projects have evalu-
ated a number of strategies, including sex-positive
materials targeted at young people, fixed facilities and
Table 1 Oral PrEP efficacy in women in 5 efficacy trials
Trial PrEP efficacy (in women) Ref
Partners PrEP
TDF-FTC 66% (p = 0.005) [5]
TDF 71% (p = 0.002) [5]






Miner et al. Trials          (2021) 22:778 Page 4 of 8
mobile delivery models, drug-level feedback counselling,
use of social clubs, and integration with services such as
gender-based violence prevention. The demonstration
projects have indicated that PrEP uptake, which varies
across regions from 36 to 98%, increases when it is part
of a broader prevention package that includes peer sup-
port, mobile services, and convenient operating times, or
as part of a sexual reproductive health package. The
working group has also investigated ways to reduce
the burden of repeated visits for PrEP, particularly be-
cause the goal is to provide a convenient service for
healthy populations. Finally, it is critical to train
health care workers and ensure their positive attitudes
in prescribing PrEP.
It is predicted that PrEP uptake will be variable and
likely evolve over time. Clinical trialists should agree on
an adequate package for adherence support and
recognize that patterns of PrEP use will most likely vary
over the course of a trial.
Designing clinical trials in the era of PrEP
Offering PrEP to vaccine or placebo recipients in an
HIV vaccine clinical trial will not truly disturb the ability
to answer the question at hand: whether the new vaccine
prevents HIV acquisition. This is true for most HIV vac-
cine studies, as the two modalities typically have differ-
ent mechanisms of action. It would, however, have an
impact. If participants use PrEP effectively, HIV inci-
dence would decrease and therefore affect the statistical
power of the primary objective (i.e. vaccine efficacy). For
example, the HIV vaccine trial HVTN 505 increased its
sample size from 1350 to 2500 participants to accommo-
date for PrEP use [48]. As such, consideration of PrEP
provision must be addressed and analysed by statisti-
cians early during the trial design process so that the sci-
entific validity of the study is not compromised.
Another issue to consider is how PrEP provision is
paid for. Most HIV prevention trials conducted in South
Africa are sponsored by the US government (via the
NIH), which stipulates research funds cannot be used
for medication and SoC procedures, including lab work.
The HVTN has previously raised philanthropic dollars
to provide TDF/FTC through an online pharmacy when
a participant received a prescription from their phys-
ician. This preserved community equity as well as less-
ened the potential burden on CRS staff of medical care
that could detract from the necessary documentation
and effort required to perform the trial. Typical vaccine
efficacy trials last 5 years, and because NIH-sponsored
trials are reliant on governmental budgeting, there is
never a guarantee that grant funding will continue. In
this system, an organization such as the HVTN can only
guarantee PrEP access for the life of the trial. Ideally,
local governments in the region a trial is conducted will
step up at that point to provide post-trial access.
Representatives from pharmaceutical companies spon-
soring clinical trials have acknowledged the importance
of providing post-trial access to interventions that work.
As these companies are themselves benefitting from the
participants in a trial, the argument could be made that
the companies owe the participants. There is precedent
for including language in trial protocols that the sponsor
will continue to provide access to a medication until it is
accessible to study participants elsewhere. This post-trial
access, some argue, is the industry’s responsibility. As
PrEP could offer a population-level reduction in HIV
prevalence, post-trial access would also provide benefit
to local communities where the trials are conducted.
Community voices should be considered when
implementing PrEP access in clinical trials
The benefits of community engagement and collabor-
ation between clinical trial networks and community ad-
vocates are well documented [49–51]. Community
Advisory Board (CAB) members are integral colleagues
in the operations of trials conducted by the US NIH-
funded HIV/AIDS networks, such as the HVTN. CABs
help ensure that SoC given to clinical trial participants
are ethical, scientifically valid, and developed with sin-
cere collaboration with communities and advocates. In
regard to HIV prevention trials conducted in South Af-
rica, community stakeholder involvement in decision-
making on PrEP provision is essential to ensuring proto-
cols are acceptable to trial participants. As such, advo-
cates and community representatives should be engaged
in the design of the PrEP plans. Communities should
feel ‘ownership’ rather than ‘buy-in.’ It is also important
there be a mechanism for advocates and community
members to monitor and inform SoC evolution so that
the care is accountable, transparent, and client centred.
As there are approximately 2000 new HIV infections
in young women in South Africa each week, it is impera-
tive that if an effective agent against HIV acquisition ex-
ists, its use should not be put on hold. Clinical trial
participants will need choices for HIV prevention; a one-
size-fits-all approach will not likely make a significant
dent in acquisition rates. PrEP should be provided to
participants who choose to take it either through easily
accessible health care organizations/clinics in the region
or by the clinical trial sites themselves. In addition, the
success of PEPFAR in ART provision in Africa can be
viewed as a model for government action to drastically
increase access to PrEP [52].
Conclusions
The topic of how to use PrEP ethically, safely, and effect-
ively has been a key consideration in the planning of
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prevention trials planned for South Africa. The recom-
mendations of the Ministry of Health, South African
ethics boards, research teams, and the vulnerable com-
munities should be heeded in clinical trials conducted in
any LMIC. Consensus across all these stakeholders is
crucial for deciding how and when to provide access to
modalities that have not yet fully bloomed in-country.
During the SoC summit discussions, it became clear
that HIV prevention researchers should move towards
making PrEP available as part of the HIV prevention
package for study participants of a clinical trial. South
African investigators and collaborators, including the
NIH’s two largest clinical trial networks working in
South Africa (HVTN and HPTN), proposed to work to-
gether as standard of prevention services evolve in
southern Africa. The scientific validity of a clinical trial
must be considered in decisions made regarding PrEP
access. In addition, it is crucial that investigators engage
their government bodies or working groups to motivate
the support of PrEP demonstration projects close to re-
search sites, not only for PrEP access, but to also provide
HIV testing and PrEP-related safety monitoring.
This summit demonstrated that considerations of SoC
in a clinical trial setting are complex. These complexities
are dynamic and contextual nuances may vary from site
to site. Both local and international guidelines can in-
form the review and the need to modify the standard of
prevention to ensure LMIC clinical trials are performed
with the highest ethical standards.
Epilogue
Following the summit, the SAMRC, with additional sup-
port from the Fred Hutchinson Cancer Research Center
(parent institution of the HVTN) and industry partners,
set up a PrEP fund for drug acquisition and laboratory
monitoring for HIV prevention study participants across
sub-Saharan Africa. This enabled the SAMRC to purchase
PrEP at state tender prices and utilize pre-existing negoti-
ated laboratory contracts and within-study systems to ex-
tend available PrEP funds. PrEP drug provision and
related essential laboratory monitoring support were sub-
sequently initiated for interested and eligible HVTN effi-
cacy trial participants at the 24 clinical trial sites
conducting trials in sub-Saharan Africa (HVTN 702
[ClinicalTrials.gov: NCT02968849), HVTN 703/HPTN
081 [ClinicalTrials.gov: NCT02568215], and HVTN 705/
HPX2008 [ClinicalTrials.gov: NCT03060629]). PrEP was
offered at each instance of risk reduction counselling
along with other prevention methods provided during
participant study visits and during the informed consent
process. Where possible, sites could offer PrEP from their
own pharmacies and staff were trained to prescribe and
manage PrEP initiation and follow-up. Each clinical site
received an up-to-date list of pharmacies and clinics that
stocked and prescribed PrEP in their areas. PrEP training
for site staff was offered periodically to enable PrEP pre-
scribing and management. The more recent HPX3002/
HVTN 706 (Mosaico) trial conducted amongst MSM and
transgender individuals in the Americas and Europe of-
fered a slightly different approach to PrEP administration
to ensure all participants could receive access to the high-
est standard of prevention. The trial was designed to give
volunteers three options regarding PrEP: (1) participants
already on PrEP or who wished to take PrEP will not be
included in the study, but referred to PrEP resources in
their community if requested; (2) participants who decide
to take PrEP after receiving vaccination can remain in the
study; and (3) participants not wanting to take PrEP can
be included in the study [53].
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